| Time(KST) | Program | Speaker |
| 08:30-09:00 | Registration | |
| 09:00-09:15 | Welcoming Remarks (KDCA) | Jee, Young-mee (Commissioner, Korea Disease Control and Prevetion Agency) |
| Opening Remarks (KNIH) | Park, Hyun-Young (Director, the Korea National Institute of Health) |
|
| Greeting Speech (KNIID) | Jang, Hee-Chang (Director, Korea National Institute of Infectious Diseases) |
|
| 09:15-09:25 | [Keynote speech 1] Development Strategies and Plans for the Therapeutics within 100/200 Days in Preparation for the Novel Infectious Disease Pandemic |
Kim, Kyung-Chang (Division Director, Korea Disease Control and Prevention Agency, National Institute of Health) |
| 09:25-09:35 | [Keynote speech 2] Development Strategies and Plans for the Vaccines within 100/200 Days in Preparation for the Novel Infectious Disease Pandemic |
Lee, Yoo-Kyoung (Division Director, Korea Disease Control and Prevention Agency, National Institute of Health) |
Session 1. Characteristics of Emerging Infectious Diseases and clinical studies Chair: Park, Man-Seong(Professor, Korea University) |
||
| 09:35-09:50 | Age-depedent differential pathogenesis of SFTSV infections | Choi, Young-Ki (Director, Korea Virus Research Institute) |
| 09:50-10:05 | Deglycosylation of human influenza A virus (H3N2) hemagglutinine increases virulence in mice. | Choi, Jang-Hoon (Research officer, KNIID) |
| 10:05-10:20 | Clinical presentation and viral shedding in patients with Mpox in South Korea | Kim, Min-kyung (Professor, National Medical Center) |
| 10:20-10:35 | Long COVID Research Project in South Korea : What we've learned about long COVID | Lee, Ja-Cob (Professor, Hallym University) |
| 10:35-10:45 | Q&A | |
| 10:45-11:00 | Break | |
Session 2. Current status and strategies for the development of therapeutics for Emerging Infectious Diseases Chair: Kim, Ki-Soon(Professor, Korea University) |
||
| 11:00-11:15 | Platforms & Tools to Enable Rapid Pandemic Response | Dimitri Lavillette (Chief Scientific Officer, Institut Pasteur Korea) |
| 11:15-11:30 | Development of SARS-CoV-2 S2 Targeted Vaccines and Therapeutic Antibodies | Cho, Eun-Wie (Principal Researcher, Korea Research Institute of Bioscience and Biotechnology) |
| 11:30-11:45 | Lessons from COVID-19 for the development of antiviral drugs | Han, Soo-Bong (Director, Korea Institute of Chemical Technology) |
| 11:45-12:00 | Acceleration of drug discovery with AI | Kim, Woo-Yeon (Professor, Korea Advanced Institute of Science and Technology) |
| 12:00-12:10 | Q&A | |
| 12:10-13:00 | Lunch | |
Session 3. Outstanding Achievements in the Development of Vaccines for Emerging Infectious Diseases Chair: Seong, Baik-Rin(Professor, Yonsei University) |
||
| 13:00-13:15 | Rapid screening of target antigenic site for vaccine development using Fv-antibody library | Pyun, Jae-Chul (Professor, Yonsei University) |
| 13:15-13:30 | HAs-NAu strategy for the development of better influenza | Kim, Jin-Il (Professor, Korea University) |
| 13:30-13:45 | SFTS mRNA Vaccine Research and Development | Kim, Hyeon Guk (Research officer, KNIID) |
| 13:45-14:00 | Broad Spectrum Vaccine and mAbs for Sarbecoviruses | Wang Linfa Professor, DUKE-NUS, Singapore Executive Director for the Programme for Research in Epidemic Preparedness and Response (PREPARE), Singapore |
| 14:00-14:10 | Q&A | |
| 14:10-14:25 | Break | |
Session 4. Current Status and Strategies in the Development of Vaccines for Emerging Infectious Disea Chair: Hong, Kee-Jong(Professor, Gachon University) |
||
| 14:25-14:40 | Vaccine adjuvant platform | Yeom, Jeong-Seon (CEO, CHA Vaccine Institute) |
| 14:40-14:55 | SKY mRNA Platform for Prophylactic Vaccine Development | Jinan Shin (Vice President, SK biosciece) |
| 14:55-15:05 | Research and Development Strategy for RSV Vaccine | Kim, Seok-Kyu (Director, U Biologics) |
| 15:05-15:15 | Strategy to develop effective multivalent COVID-19 vaccines against emerging variants based on adenovirus vector platform | Kang, Chang-Yul (CEO, CELLID) |
Panel Discussion Chair: Seong, Baik-Rin(Professor, Yonsei University) |
||
| 15:15-15:55 | Q&A and Future Collaboration Prospectsl * Therapeutics: - Kim, Kyung-Chang(Division Director, Korea Disease Control and Prevention Agency, National Institute of Health) - Dimitri Lavillette(Chief Scientific Officer, Institut Pasteur Korea) - Han, Soo-Bong (Director, Korea Institute of Chemical Technology) - Kim, Woo-Yeon (Professor, Korea Advanced Institute of Science and Technology) * Vaccines: - Lee, Yoo-Kyoung(Division Director, Korea Disease Control and Prevention Agency, National Institute of Health) - Yeom, Jeong-Seon(CEO, CHA Vaccine Institute) |
|
| 15:55-16:00 | Closing Remarks (KNIID) | |
